Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TBPH

Theravance Biopharma Inc

Apr 16 • 04:00PM ET

16.78

+0.14 0.84 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN GILD BMRN INCY IONS NBIX ALNY MDGL SRPT

| Held by: VTI IWM VXF PBE IBB CALF XPH IWO JSMD VTWO

Scroll to Statements

Index	RUT	P/E	8.28	EPS (ttm)	2.03	Insider Own	6.62%	Shs Outstand	51.07M	Perf Week	1.39%
Market Cap	864.05M	Forward P/E	11.58	EPS next Y	1.45	Insider Trans	-1.79%	Shs Float	48.08M	Perf Month	20.55%
Enterprise Value	624.19M	PEG	-	EPS next Q	0.03	Inst Own	96.57%	Short Float	10.95%	Perf Quarter	-18.58%
Income	105.89M	P/S	8.04	EPS this Y	23.46%	Inst Trans	4.31%	Short Ratio	8.41	Perf Half Y	21.16%
Sales	107.46M	P/B	2.89	EPS next Y	-43.02%	ROA	25.22%	Short Interest	5.26M	Perf YTD	-10.32%
Book/sh	5.81	P/C	2.74	EPS next 5Y	-25.73%	ROE	44.85%	52W High	21.03 -20.21%	Perf Year	95.23%
Cash/sh	6.12	P/FCF	3.62	EPS past 3/5Y	- -	ROIC	29.31%	52W Low	8.33 101.44%	Perf 3Y	40.77%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	27.91% 8.38%	Gross Margin	94.75%	Volatility	2.59% 3.22%	Perf 5Y	-22.71%
Dividend TTM	-	EV/Sales	5.81	EPS Y/Y TTM	281.10%	Oper. Margin	-7.77%	ATR (14)	0.56	Perf 10Y	-25.22%
Dividend Ex-Date	-	Quick Ratio	10.93	Sales Y/Y TTM	66.92%	Profit Margin	98.54%	RSI (14)	61.12	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.93	EPS Q/Q	465.26%	SMA20	6.34%	Beta	0.19	Target Price	17.20
Payout	0.00%	Debt/Eq	0.25	Sales Q/Q	144.70%	SMA50	1.22%	Rel Volume	0.84	Prev Close	16.64
Employees	90	LT Debt/Eq	0.22	Earnings	Mar 19 BMO	SMA200	7.22%	Avg Volume	625.42K	Price	16.78
IPO	May 16, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.26% -18.90%	Trades		Volume	526,644	Change	0.84%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-05-26	Downgrade	Oppenheimer	Outperform → Perform
Mar-04-26	Downgrade	B. Riley Securities	Buy → Neutral	$14
Dec-03-25	Initiated	Oppenheimer	Outperform	$27
Sep-12-25	Initiated	B. Riley Securities	Buy	$28
Aug-06-24	Downgrade	Leerink Partners	Outperform → Market Perform	$15 → $10
Apr-12-24	Initiated	BTIG Research	Buy	$21
Jan-08-24	Downgrade	Evercore ISI	Outperform → In-line
May-23-22	Initiated	SVB Leerink	Outperform	$12
Nov-05-21	Upgrade	JP Morgan	Underweight → Neutral	$12
Sep-15-21	Downgrade	JP Morgan	Overweight → Underweight	$7
Aug-25-21	Downgrade	Morgan Stanley	Overweight → Underweight	$27 → $14
Aug-24-21	Downgrade	Cowen	Outperform → Market Perform	$42 → $14
Oct-14-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$32
Jul-07-20	Initiated	JP Morgan	Overweight	$29
Jun-15-20	Initiated	Morgan Stanley	Equal-Weight	$30
May-13-20	Initiated	Cowen	Outperform	$42
Jan-08-20	Reiterated	H.C. Wainwright	Buy	$25 → $30
Nov-06-19	Upgrade	Robert W. Baird	Underperform → Neutral	$22 → $18
Oct-29-19	Initiated	H.C. Wainwright	Buy	$25
Mar-29-18	Resumed	Piper Jaffray	Overweight	$45

Show Previous Ratings

Mar-19-26 08:37AM	Theravance Bio: Q4 Earnings Snapshot (Associated Press Finance)
08:30AM	Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (PR Newswire)
Mar-18-26 10:00AM	TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP (PR Newswire)
Mar-09-26 09:35AM	Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH) (Zacks)
Mar-06-26 09:35AM	Down 30.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH) (Zacks)
10:34AM	Loading…
Mar-04-26 10:34AM	TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study (Zacks)
07:32AM	Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure (Clinical Trials Arena)
Mar-03-26 04:18PM	The Excruciating Failure That Could Prompt Theravance, Down 26%, To Sell Itself (Investor's Business Daily) -26.33%
01:19PM	Theravance Biopharma Plummets As Phase 3 Study Falls Short (Benzinga)
11:05AM	Theravance Biopharma shares plunge 26% after drug trial failure triggers strategic review (Proactive)
08:30AM	Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions (PR Newswire)
Feb-24-26 08:02AM	CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet? (Zacks)
Jan-28-26 01:15PM	Is the Options Market Predicting a Spike in Theravance Biopharma Stock? (Zacks)
Jan-23-26 09:50AM	Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-15-26 09:45AM	Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term (Zacks)
09:50AM	Loading…
Jan-06-26 09:50AM	Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term (Zacks)
Dec-24-25 09:45AM	Here's Why Theravance Biopharma (TBPH) is a Strong Growth Stock (Zacks)
Dec-22-25 09:55AM	Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here's is How to Trade (Zacks)
Dec-10-25 11:30AM	Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-08-25 12:00PM	Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy? (Zacks)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-05-25 09:55AM	Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect? (Zacks)
09:45AM	Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term (Zacks)
Nov-20-25 11:00AM	Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 (PR Newswire)
09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
Nov-19-25 09:45AM	Theravance Biopharma (TBPH) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
06:00AM	Theravance Biopharma to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-11-25 02:14PM	Here's Why Shares in Theravance Biopharma Exploded Today (Motley Fool) +22.68%
10:10AM	Theravance's Q3 Earnings Surpass Estimates, Revenues Match (Zacks)
12:04AM	Theravance Biopharma Inc (TBPH) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
05:20PM	Loading…
Nov-10-25 05:20PM	Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates (Zacks)
04:20PM	Theravance Bio: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Nov-06-25 09:15AM	VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Oct-30-25 02:05PM	CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy? (Zacks)
Oct-29-25 06:00AM	Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System (PR Newswire)
Oct-27-25 06:00AM	Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 (PR Newswire)
Oct-16-25 08:05AM	Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy (Business Wire)
Oct-14-25 06:00AM	Theravance Biopharma to Present New Analyses Highlighting YUPELRI (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting (PR Newswire)
Sep-11-25 11:30AM	Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-02-25 06:00AM	Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-25-25 06:00AM	Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy (PR Newswire)
Aug-13-25 12:31PM	Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
03:14AM	Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ... (GuruFocus.com)
Aug-12-25 05:25PM	Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:23PM	Theravance Bio: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Aug-11-25 09:29AM	Theravance Biopharma Inc (TBPH) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-07-25 08:25AM	Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2 (Zacks)
Jul-28-25 06:00AM	Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025 (PR Newswire)
Jul-23-25 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Jul-17-25 09:11AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics (Zacks)
Jul-16-25 09:01AM	5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats (Zacks)
Jul-15-25 08:59AM	Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma (Insider Monkey)
Jun-27-25 07:36AM	Viatris gains China approval for Yupelri to treat COPD (Pharmaceutical Technology)
Jun-26-25 06:00AM	Theravance Biopharma Announces Approval of YUPELRI (revefenacin) by China's NMPA (PR Newswire)
Jun-03-25 11:53AM	TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises (Zacks)
Jun-02-25 06:00AM	Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million (PR Newswire) +21.72%
May-13-25 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
May-09-25 12:39PM	Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y (Zacks) -9.29%
12:00PM	Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress (PR Newswire)
03:47AM	Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
May-08-25 06:05PM	Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
May-07-25 10:52AM	Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-06-25 05:30PM	Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates (Zacks)
Apr-28-25 06:00AM	Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress (PR Newswire)
Apr-24-25 06:00AM	Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 (PR Newswire)
Apr-07-25 03:55PM	Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting (PR Newswire)
Mar-31-25 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Mar-28-25 11:30AM	Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report? (Zacks)
Mar-27-25 06:00AM	Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology (PR Newswire)
Feb-27-25 02:26AM	Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Feb-26-25 05:15PM	Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-25-25 10:55AM	Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 2024 Result (GuruFocus.com)
Feb-20-25 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Feb-12-25 06:00AM	Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 (PR Newswire)
Feb-05-25 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Jan-27-25 03:57AM	Theravance Bio (TBPH) Soars 8.3%: Is Further Upside Left in the Stock? (Zacks) -7.64%
Jan-18-25 08:20AM	Ozempic, Xtandi among next 15 drugs selected for U.S. price talks (TipRanks)
Dec-19-24 08:00AM	Government Contractor KBR, Recently Hit by DOGE Fears, Draws Activist Investor (The Wall Street Journal)
Dec-17-24 06:00AM	Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference (PR Newswire)
Dec-12-24 11:30AM	Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-20-24 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Nov-13-24 02:22AM	Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) +8.64%
Nov-12-24 06:05PM	Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value (PR Newswire)
Nov-11-24 07:16AM	What To Expect From Theravance Biopharma Inc (TBPH) Q3 2024 Earnings (GuruFocus.com)
Oct-24-24 06:00AM	Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024 (PR Newswire)
Oct-18-24 09:00AM	Theravance Announces Publication of YUPELRI (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease (PR Newswire)
Sep-10-24 11:01AM	Seth Klarman's Complete Exit from Theravance Biopharma Inc (GuruFocus.com)
Sep-04-24 11:30AM	Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-27-24 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Aug-14-24 05:03PM	Seth Klarman's Strategic Reduction in Theravance Biopharma Inc (GuruFocus.com)
Aug-06-24 10:56AM	Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y (Zacks) -18.35%
Aug-05-24 06:00PM	Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Jul-25-24 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Jul-22-24 06:00AM	Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024 (PR Newswire) +7.00%

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the following geographical segments: U.S. and Europe. The company was founded in July 2013 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Mar 16 '26	Sale	13.96	31,067	433,637	232,699	Mar 18 06:12 PM
RHONDA FARNUM	Officer	Mar 16 '26	Proposed Sale	13.96	31,067	433,637		Mar 16 04:17 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Dec 03 '25	Sale	18.75	31,067	582,501	277,695	Dec 05 06:02 PM
RHONDA FARNUM	Officer	Dec 03 '25	Proposed Sale	18.75	31,067	582,500		Dec 03 04:19 PM
ERAN BROSHY	Director	Nov 26 '25	Proposed Sale	20.00	29,501	590,020		Nov 26 04:02 PM
ERAN BROSHY	Director	Nov 11 '25	Proposed Sale	17.98	45,000	809,250		Nov 12 09:02 AM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jul 14 '25	Sale	11.39	10,000	113,870	326,918	Jul 16 06:01 PM
RHONDA FARNUM	Officer	Jul 14 '25	Proposed Sale	11.39	10,000	113,869		Jul 14 04:03 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jun 02 '25	Sale	11.00	24,000	264,000	336,918	Jun 04 06:04 PM
RHONDA FARNUM	Officer	Jun 02 '25	Proposed Sale	11.00	24,000	264,000		Jun 02 04:25 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Apr 21 '25	Sale	9.00	4,000	36,000	370,038	Apr 23 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TBPH

Theravance Biopharma Inc

Upgrade your Finviz experience